a Personalized Medicine Institute and Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, Florida; Foundation Medicine, Inc., Cambridge, Massachusetts; and Department of Radiology, Sarcoma Department, and Chemical Biology and Molecular Medicine Program, Moffitt Cancer Center, Tampa, Florida.
Kaposi sarcoma (KS) is an uncommon angioproliferative malignancy that is associated with human herpesvirus 8. Although there has been recent enthusiasm for evaluating immune checkpoint inhibition as a therapeutic option for viral-associated tumors, the clinical utility in this disease is currently unknown. We report a case of advanced classic KS refractory to multiple lines of chemotherapy that experienced a partial response to anti–PD-1 therapy. Comprehensive molecular profiling was performed on a diagnostic tumor biopsy sample. Molecular profiling data from 8 additional male patients with KS were reviewed and compared with those of the index case. The genomic profile of the index case was notable for higher-than-typical somatic mutational burden, including pathogenic mutation in multiple well-described cancer genes, such as TP53, CDKN2A, NOTCH1, and KRAS. Our case suggests that further clinical study of checkpoint inhibitor therapy in classic KS is warranted, and provides a hypothesis for future immunogenomic biomarker analysis in this disease.
Correspondence: Andrew S. Brohl, MD, Sarcoma Department, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Email: email@example.com
Di LorenzoG, KreuterA, Di TrolioR. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol2008;128:1578–1580.
Di LorenzoGKreuterADi TrolioR. Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study. J Invest Dermatol2008;128:1578–1580.